Clinical Trials

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03547115 2026-03-17

A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML

84 enrolled

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04588922 2026-03-16

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

160 enrolled

Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT07387471 2026-03-16

Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

14 enrolled

Waldenstrom Macroglobulinemia, Neoplasms, Lymphoma, B-Cell, Marginal Zone

NCT05963074 2026-03-13

TAILOR

320 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03462719 2026-03-12

GLOW

211 enrolled 23 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03336333 2026-03-09

SEQUOIA

590 enrolled 12 charts 1 FDA

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03844048 2026-03-06

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

165 enrolled

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03331198 2026-03-04

Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

320 enrolled

Phase 1/2 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04623541 2026-03-04

EPCORE™ CLL-1

195 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06073821 2026-03-04

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

652 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06943872 2026-03-04

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

Phase 3 Recruiting

630 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05091424 2026-03-03

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

Phase 1 Recruiting

137 enrolled

Phase 2 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06524375 2026-02-25

BRAVE

118 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05057494 2026-02-18

MAJIC

607 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04895436 2026-02-09

ReVenG

75 enrolled

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03123029 2026-01-30

Expanded Access to Venetoclax

Available

Amyloidosis, Leukemia, Plasma Cell, Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04965493 2026-01-29

BRUIN CLL-322

600 enrolled

LymphoidOther hematologic neoplasmSarcoma

Hematologic Diseases, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT03740529 2026-01-27

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

Phase 1/2 Completed

803 enrolled 2 FDA

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Dendritic Cell Sarcoma, Interdigitating

NCT07024706 2026-01-21

MAVRiC

Phase 2 Not yet recruiting

80 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02966756 2025-12-24

A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

110 enrolled

Chromosome 17 deletion, Leukemia, Lymphoproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell

NCT07154264 2025-12-24

A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)

66 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02296918 2025-12-19

Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL

Phase 1 Completed

69 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic

NCT04068597 2025-12-18

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

250 enrolled

445 enrolled 22 charts 1 FDA

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

NCT02242942 2025-11-06

Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

Phase 3 Completed

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06428019 2025-11-05

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Phase 3 Recruiting

170 enrolled

Phase 2 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05951959 2025-10-21

TrAVeRse

108 enrolled

Lymphoma, Lymphoma, Mantle-Cell

NCT05105841 2025-10-15

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Phase 2 Completed

20 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04607772 2025-10-03

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 1/2 Withdrawn

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03112174 2025-07-22

SYMPATICO

Phase 3 Completed

366 enrolled 45 charts

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT04477486 2025-07-09

Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma

Phase 2 Completed

13 enrolled 10 charts

Lymphoma, Mantle-Cell

NCT03492125 2025-04-10

A Study Of The Selective PKC-β Inhibitor MS- 553

Phase 1/2 Terminated

60 enrolled 20 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04988555 2025-04-02

A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation

362 enrolled

Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04553692 2025-03-28

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

GastrointestinalLymphoidOther hematologic neoplasmSarcoma

272 enrolled

Chondrosarcoma, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

NCT04419389 2025-03-17

R/R

Phase 1/2 Terminated

1 enrolled 4 charts

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT03836261 2024-12-27

AMPLIFY

984 enrolled 1 FDA

Leukemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02910583 2024-12-20

Captivate

Phase 2 Completed

323 enrolled 33 charts

CNSLymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04029688 2024-12-20

A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors

Phase 1/2 Terminated

38 enrolled 34 charts

Neuroblastoma, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03530683 2024-09-03

A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

189 enrolled

Leukemia, Lymphoma, Multiple Myeloma, Neoplasms, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Neoplasms, Plasma Cell

NCT03557619 2024-08-29

A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies

Phase 1 Recruiting

12 enrolled

Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Hematologic Neoplasms

NCT03406156 2024-08-06

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

Phase 3 Completed

120 enrolled 14 charts

Chromosome 17 deletion, Neoplasms, Tumor Lysis Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04790903 2024-07-11

A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)

50 enrolled

LymphoidMyeloidOther hematologic neoplasm

Lymphoma, Large B-Cell, Diffuse

NCT03592576 2024-05-06

Expanded Access to Navitoclax

No longer available

Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT03801525 2024-04-19

ULTRA-V

Phase 2/3 Terminated

277 enrolled 19 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05107856 2024-01-31

PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies